Purified chick embryo cell (PCEC) rabies vaccine for human use. Laboratory data

Area of Science:

• Virology
• Vaccinology
• Public Health

Background:

• Rabies remains a significant global health threat requiring effective vaccination strategies.
• Existing human rabies vaccines include the Human Diploid Cell Strain rabies vaccine (HDCSV).
• Development of novel, safe, and effective rabies vaccines is crucial for disease prevention.

Purpose of the Study:

• To develop and characterize a new inactivated rabies vaccine using Purified Chick Embryo Cell culture (PCEC).
• To evaluate the innocuity, tolerability, and protective capacity of the PCEC rabies vaccine.
• To compare the PCEC vaccine's performance against the established HDCSV.

Main Methods:

• Adaptation of the FLURY-LEP C25 rabies virus strain for propagation in primary chick embryo cell cultures.
• Purification and concentration of the viral antigen using continuous density gradient centrifugation.
• Inactivation of the antigen using Betapropiolactone, followed by laboratory testing for safety and efficacy.

Main Results:

• The PCEC-rabies vaccine demonstrated excellent tolerability in laboratory tests.
• The vaccine exhibited protective activity comparable to the HDCSV.
• Pre-clinical laboratory assessments met stringent requirements for initiating human trials.

Conclusions:

• The PCEC-rabies vaccine is a promising new candidate for human rabies prophylaxis.
• Its safety and efficacy profile in laboratory studies supports its advancement to clinical trials.
• This vaccine represents a potential new tool in the global effort to control and eliminate rabies.